Skip to main content
Annals of Intensive Care

Table 2 Admission characteristics associated with hospital mortality censored at day 60 amongst patients admitted in the pre- and post-implementation periods

From: Impact of a multidisciplinary care bundle for necrotizing skin and soft tissue infections: a retrospective cohort study

 

Available data

Survivors

n = 151

Non-survivors

n = 38

Unadjusted hazard ratio [95% CI]a

p b

Adjusted hazard ratio [95% CI]c

p d

Inclusion period, n (%)

  

 Post-implementation

129

109 (72.2)

20 (52.6)

0.49 [0.26–0.92]

0.026

0.90 [0.43–1.88]

0.780

 Pre-implementation

60

42 (27.8)

18 (47.4)

–

–

  

Demographical data

  

 Age, years, median (IQR)

189

61 [51–72]

71 [59–80]

1.00 [1.00–1.10]

0.018

1.04 [1.01–1.07]

0.011

 Male gender, n (%)

86 (57.0)

24 (63.2)

–

0.510

  

Comorbidities, n (%)

  

 Diabetes mellitus

189

58 (38.4)

13 (34.2)

–

0.520

  

 Immunodeficiency

26 (17.2)

18 (47.4)

3.30 [1.70–6.20]

< 0.001

2.20 [1.09–4.44]

0.028

  HIV infection

1 (0.7)

0 (0.0)

–

> 0.99

  

  Cancer

9 (6.0)

5 (13.2)

–

0.140

  

  Corticosteroids

16 (10.6)

11 (28.9)

2.70 [1.40–5.50]

0.005

  

 Obliterating arteritis of the lower limbs

15 (9.9)

5 (13.2)

–

0.580

  

 Liver cirrhosis

4 (2.6)

3 (7.9)

–

0.100

  

 Chronic kidney disease

10 (6.6)

10 (26.3)

3.50 [1.70–7.20]

< 0.001

–

–

 Chronic alcohol consumption

20 (13.2)

2 (5.3)

–

0.190

  

 Obesity

42 (27.8)

5 (13.2)

–

0.061

  

Prior to admission

  

 Time from first symptom, days, median (IQR)

180

5 [3–9]

3 [1–8]

–

0.410

  

 Antibiotic treatment, n (%)

187

99 (65.6)

18 (47.4)

0.51 [0.27–0.97]

0.041

0.36 [0.17–0.75]

0.006

 NSAID use, n (%)

188

38 (25.2)

4 (10.5)

–

0.076

  

 Transferred from another center, n (%)

189

79 (52.3)

21 (55.3)

–

0.670

  

Presentation upon admission

  

 Nosocomial infection, n (%)

188

24 (15.9)

13 (34.2)

2.50 [1.30–5.00]

0.007

2.28 [1.00–5.16]

0.049

 Infection site, n (%)

188

   

  Inferior limbs

114 (75.5)

29 (76.3)

–

0.600

  

  Superior limbs

15 (9.9)

3 (7.9)

–

0.690

  

  Abdomino-perineal

27 (17.9)

7 (18.4)

–

0.960

  

  Cervico-facial

2 (1.3)

0 (0.0)

–

> 0.99

  

  Other

1 (0.7)

0 (0.0)

–

> 0.99

  

 Multifocal infection, n (%)

188

14 (9.3)

5 (13.2)

–

0.540

  

 Shock, n (%)

185

48 (31.8)

31 (81.6)

8.20 [3.40–20.00]

< 0.001

8.13 [3.26–20.20]

< 0.001

  1. HIV human immunodeficiency virus, NSAID non-steroidal anti-inflammatory drugs
  2. Univariable and multivariable analysis by Cox proportional hazards model. Multivariable analysis for 179 patients (10 excluded for missing data on one of the variables)
  3. a,bHazard ratios and p values from the comparison of survivors and non-survivors by univariate cox regression analysis for survival censored at 60 days
  4. c,dAdjusted hazard ratios and p values from a multivariate cox model for survival censored at 60 days. Only patients from the pre- and post-implementation periods were included in the analysis. Variables included in the model were all variables available upon admission associated with mortality in the univariate model with a p value inferior or equal to 0.05. Corticosteroid treatment was included as part of immunodeficiency. Included variables with a p value > 0.1 (chronic kidney disease) in the multivariate model were excluded from the final model
Back to article page